Status:
RECRUITING
Daily Aspirin Treatment After Preeclampsia
Lead Sponsor:
Anna Stanhewicz, PhD
Conditions:
Preeclampsia
Eligibility:
FEMALE
18-50 years
Phase:
EARLY_PHASE1
Brief Summary
Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be relate...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- had preeclampsia in the past 5 years,
- 18 years or older
- Exclusion criteria:
- current daily aspirin use,
- skin diseases,
- current tobacco or nicotine use (including vaping),
- diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \< 60 mL/min/1.73m2,
- statin or other cholesterol-lowering medication,
- current antihypertensive medication,
- history of hypertension prior to pregnancy,
- history of gestational diabetes,
- currently pregnancy,
- body mass index \<18.5 kg/m2,
- allergy to materials used during the experiment.(e.g. latex),
- known allergies to study drugs,
- bleeding disorders, peptic ulcer disease, gastritis, GI bleeding and gastroesophageal reflux disease (GERD).
Exclusion
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06168461
Start Date
November 1 2023
End Date
June 1 2026
Last Update
December 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Iowa
Iowa City, Iowa, United States, 52242